eHealth for inflammatory bowel disease self-management – the patient perspective

Abstract

Background: Electronic health (eHealth) solutions may help address the growing pressure on IBD outpatient services as they encompass a component of self-management. However, information regarding patients’ attitudes towards the use of eHealth solutions in IBD is lacking.

Objective: The aim of this study was to evaluate eHealth technology use and explore the perspectives of IBD patients on what constitutes the ideal eHealth solution to facilitate self-management.

Methods: A mixed methods qualitative and quantitative analysis of the outcomes of a discussion forum and an online survey conducted at a tertiary hospital in Melbourne, Australia between November 2015 and January 2016 was undertaken.

Results: Eighteen IBD patients and parents participated in the discussion forum. IBD patients expressed interest in eHealth tools that are convenient and improve access to care, communication, disease monitoring and adherence. Eighty six patients with IBD responded to the online survey. A majority of patients owned a mobile phone (98.8%), had access to the internet (97.7%), and felt confident entering data onto a phone or computer (73.3%). Most patients (98.8%) were willing to use at least one form of information and communication technology to help manage their IBD. Smartphone apps and internet websites were the two most preferred technologies to facilitate IBD self-management.

Conclusions: This study demonstrates the willifngness of patients to engage with eHealth as a potential solution to facilitate IBD self-management. Future development and testing of eHealth solutions should be informed by all major stakeholders including patients to maximise their uptake and efficacy to facilitate IBD self-management.

Keywords:

• IBD
• eHealth
• self-management
• participatory medicine

Acknowledgements

The Gutsy Group provided research support. Ferring provided an unrestricted educational grant. AbbVie provided research support. PDC is supported by a David Bickart Clinician Research Award from the University of Melbourne and Bushell Postdoctoral Award from the Gastroenterological Society of Australia (GESA). BJ is supported by a National Health and Medical Research Council (NHMRC) postgraduate scholarship and AVANT Doctor in Training (DiT) scholarship.

Disclosure statement

PDC has received educational support, consulted on advisory boards and been a speaker at educational symposia sponsored by Shire, Ferring, Janssen, AbbVie, Takeda and Baxter. BJ has received educational support from Shire and Takeda, Ferring, Norgine, and Janssen.

Additional information

Funding

The Gutsy Group provided research support. Ferring provided an unrestricted educational grant. AbbVie provided research support. PDC is supported by a David Bickart Clinician Research Award from the University of Melbourne and Bushell Postdoctoral Award from the Gastroenterological Society of Australia (GESA). BJ is supported by a National Health and Medical Research Council (NHMRC) postgraduate scholarship and AVANT Doctor in Training (DiT) scholarship.